Last year, sales of hemophilia A treatment in hospitals and clinics were tallied at 66 billion won. While existing major drugs are sluggish in hospitals and clinics, JW Pharmaceutical's Hemlibra, which recently joined the market, has risen in sales for two consecutive years, rising to No. 2 in the market. In the pharmaceutical industry, sales of Hemlibra are expected to increase further as benefits for Hemlibra are expected to increase in the first half. As a result, there is a prospect that the hemophilia A treatment market, which has been led by GC Pharma, will be greatly shaken.

According to IQVIA, a pharmaceutical market research institute on the 7th, sales of hemophilia A treatment to hospitals an